Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review
Therapeutische Effekte von Low-Dose-Psilocybin bei Depression und anderen psychischen Störungen: systematische Übersicht
Psychedelic Medicine · 01.03.2026 · 4 (1) · 54-67
DOI: 10.1089/psymed.2024.0039 ↗Auf einen Blick
Die Übersichtsarbeit fand nur begrenzte Evidenz zu Low-Dose-Psilocybin bei psychischen Störungen. Berichtet wurden teils kurzfristige Verbesserungen, insgesamt blieb die Wirksamkeit unklar.
Fragestellung
Wie wirksam und sicher ist Low-Dose-Psilocybin bei psychischen Störungen?
Methode
Systematische Übersicht empirischer Studien zu Low-Dose-Psilocybin bei Menschen; Suche bis Juni 2024, zusätzlich nach registrierten Studien auf clinicaltrials.gov.
Ergebnisse
Einschluss von 5 registrierten klinischen Studien und 6 Publikationen: 3 RCTs, 2 Studien zu sekundären Endpunkten und 1 Fallbericht. Ein RCT berichtete bei 1 mg eine MADRS-Verbesserung von −5,4 (95 %-KI −8,1 bis −2,7) nach 3 Wochen.
Einschränkungen
Es fehlen gut geplante Studien und direkte Vergleiche mit Placebo.
Schlussfolgerung der Autor:innen
Die empirische Evidenz zur Wirksamkeit von Low-Dose-Psilocybin bei psychischen Störungen ist begrenzt.
Kernaussagen
- Nur begrenzte Evidenz zu Low-Dose-Psilocybin bei psychischen Störungen
- 1 mg zeigte in einer Studie kurzfristige Verbesserungen
- Die Autor:innen fordern große, rigide RCTs zu Low-Dose-Protokollen
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Übersichtsarbeit in der Zeitschrift Psychedelic Medicine, online erschienen am 28.04.2025. Verfasst von Shakila Meshkat und 13 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Psychiatry Program, St. Michael's Hospital, Toronto, Canada. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Depression
Abstract (Originalsprache)
Introduction
High-dose psilocybin has shown potential in treating various psychiatric disorders, but its perceptual and cognitive effects, along with the risk of adverse events, highlight the need for alternative treatment approaches. One such approach is the use of low-dose psilocybin, which does not significantly alter cognition or perception. While low-dose psilocybin has garnered growing interest in the psychiatric community, its therapeutic efficacy remains unclear and warrants further investigation. This systematic review aims to evaluate the efficacy and safety of low-dose—whether in the form of microdosing or low-dose control conditions in clinical trials—psilocybin for mental disorders.
Methods
We conducted a systematic review of all empirical evidence involving low-dose psilocybin in human subjects for psychiatric treatment from inception to June 2024. We also searched for relevant registered clinical trials on clinicaltrials.gov.
Results
We identified five registered clinical trials and six publications, including randomized controlled trials (RCTs) (3, 50%), secondary outcome studies (2, 33%), and case report (1, 16%). Four studies (66%) included concurrent psychotherapy. Doses ranged from 1–3 mg per 70 kg as a single dose or 0.1–0.2 g of dried psilocybin-containing mushrooms every 3 days for up to 3 years. Two RCTs studied treatment-resistant depression with 1, 10, and 25 mg psilocybin doses. In the 1 mg group, 18% of participants showed a significant response, 8% achieved remission, and the Montgomery–Åsberg Depression Rating Scale score improved by −5.4 (95% confidence interval [CI]: −8.1 to −2.7) at week 3, though only 10% maintained this by week 12. Another study found transient improvements in anxiety and cognitive function with 1 mg. One trial reported no significant improvement with 1–3 mg doses, though 12% achieved anxiety remission and 16% depression remission. An RCT comparing 25 mg to 1 mg plus escitalopram found higher response rates with 25 mg than 1 mg group, although no significant difference in rumination or thought suppression between groups was observed.
Conclusion
The empirical evidence for the efficacy of low-dose psilocybin in treating mental disorders is limited. The current research is constrained by a lack of well-designed studies that compare low-dose psilocybin to placebo. To better understand its potential, future research should include large, rigorous RCTs specifically focused on assessing low-dose protocols.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Interventional Psychiatry Program, St. Michael's Hospital, Toronto, Canada.
- NYU Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York, New York, USA.
- Center for Psychedelic Research, Imperial College London, London, United Kingdom.
- Neurosciences & Mental Health, Hospital for Sick Children Research Institute, Toronto, Canada.
- Institute of Medical Science, University of Toronto, Toronto, Canada.
- Department of Physiology and Pharmacology, Western University, London, Canada.
ORCID-Profile: Rachel Sousa-Ho
Zitieren
APA
Meshkat, S., Fang, H., Sousa-Ho, R., Zeifman, R. J., Dunkley, B. T., Reichelt, A. C., Zhang, Y., Burback, L., Winkler, O., Greenshaw, A., Jetly, R., Mayo, L. M., Monson, C. M., & Bhat, V. (2026). Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review. Psychedelic Medicine, 4(1), 54-67. https://doi.org/10.1089/psymed.2024.0039
Vancouver
Meshkat S, Fang H, Sousa-Ho R, Zeifman RJ, Dunkley BT, Reichelt AC, et al. Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review. Psychedelic Medicine. 2026;4(1):54-67. doi:10.1089/psymed.2024.0039
BibTeX
@article{Meshkat2026,
author = {Meshkat, Shakila and Fang, Howell and Sousa-Ho, Rachel and Zeifman, Richard J and Dunkley, Benjamin T and Reichelt, Amy C and Zhang, Yanbo and Burback, Lisa and Winkler, Olga and Greenshaw, Andrew and Jetly, Rakesh and Mayo, Leah M and Monson, Candice M and Bhat, Venkat},
title = {Therapeutic Effects of Low-Dose Psilocybin in Depression and Other Mental Disorders: A Systematic Review},
journal = {Psychedelic Medicine},
year = {2026},
volume = {4},
number = {1},
pages = {54--67},
doi = {10.1089/psymed.2024.0039}
}
EUVIMED